23 January 2024
23 January 2024
Inhibrx has an extensive pipeline of new biologic therapeutic candidates, primarily focusing on oncology and orphan diseases.
The UK government adopted a series of updates to pharmaceutical laws, governing the medication landscape in 2023.
More than 3.4 million children are unprotected against the disease, as NHS urges more people to book missed vaccinations against measles, mumps, and rubella (MMR).
The decision comes after a comprehensive review of the long-term side effects associated with the drugs.
Virios will advance combination therapy IMC-2 into a Phase II study later this year, with data expected in 2025.
Processa announced plans to begin a Phase II breast cancer study for its capecitabine combination therapy in Q3 2024.
The French company will start the confirmatory trial for its cancer vaccine Tedopi as a second-line lung cancer therapy in Q2 2024.
The company plans to commence a Phase II global clinical trial of NS-229 shortly.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
